Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Distinct computed tomography features of non-small-cell lung cancer in aEuropean population with EML4-ALK translocation

Distinct computed tomography features of non-small-cell lung cancer in aEuropean population with... original report memo (2017) 10:94–102 DOI 10.1007/s12254-016-0305-1 Distinct computed tomography features of non-small- cell lung cancer in a European population with EML4-ALK translocation Ullrich G. Mueller-Lisse · Hanna A. Zimmermann · Carolina Reiners · Simone Reu · Maximilian F. Reiser · Rudolf M. Huber · Amanda Tufman Received: 4 October 2016 / Accepted: 28 November 2016 / Published online: 19 December 2016 © Springer-Verlag Wien 2016 Summary statistical tests (Fisher exact/Student-T) were used to Background Treatment of advanced EML4-ALK- compare ALK-positive and ALK-negative tumors. The translocation-positive non-small-cell lung cancer analyses took potential confounders into account in- (NSCLC) with an ALK tyrosine kinase inhibitor (TKI) cluding patient age, gender, previous NSCLC therapy, is now standard of care. Since EML4-ALK gene fusion UICC stage, and smoking status. is rare in NSCLC and testing depletes both tissue sam- Results Ten of 39 adult European Caucasian patients ples and health care funds, deciding who to screen (age 57 ± 10 years, 17 female) were ALK positive. is critical. CT features associated with EML4-ALK- Diffuse tumor growth (ALK positive 9, ALK negative positive cases may help prioritize individual patients 7/5, p < 0.0005/p < 0.0001, agreement 95%), multiple for ALK testing in settings where http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

Distinct computed tomography features of non-small-cell lung cancer in aEuropean population with EML4-ALK translocation

Loading next page...
 
/lp/springer-journals/distinct-computed-tomography-features-of-non-small-cell-lung-cancer-in-5NvKoDZbUb

References (52)

Publisher
Springer Journals
Copyright
Copyright © 2016 by Springer-Verlag Wien
Subject
Medicine & Public Health; Oncology; Medicine/Public Health, general
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-016-0305-1
Publisher site
See Article on Publisher Site

Abstract

original report memo (2017) 10:94–102 DOI 10.1007/s12254-016-0305-1 Distinct computed tomography features of non-small- cell lung cancer in a European population with EML4-ALK translocation Ullrich G. Mueller-Lisse · Hanna A. Zimmermann · Carolina Reiners · Simone Reu · Maximilian F. Reiser · Rudolf M. Huber · Amanda Tufman Received: 4 October 2016 / Accepted: 28 November 2016 / Published online: 19 December 2016 © Springer-Verlag Wien 2016 Summary statistical tests (Fisher exact/Student-T) were used to Background Treatment of advanced EML4-ALK- compare ALK-positive and ALK-negative tumors. The translocation-positive non-small-cell lung cancer analyses took potential confounders into account in- (NSCLC) with an ALK tyrosine kinase inhibitor (TKI) cluding patient age, gender, previous NSCLC therapy, is now standard of care. Since EML4-ALK gene fusion UICC stage, and smoking status. is rare in NSCLC and testing depletes both tissue sam- Results Ten of 39 adult European Caucasian patients ples and health care funds, deciding who to screen (age 57 ± 10 years, 17 female) were ALK positive. is critical. CT features associated with EML4-ALK- Diffuse tumor growth (ALK positive 9, ALK negative positive cases may help prioritize individual patients 7/5, p < 0.0005/p < 0.0001, agreement 95%), multiple for ALK testing in settings where

Journal

memo - Magazine of European Medical OncologySpringer Journals

Published: Dec 19, 2016

There are no references for this article.